key: cord-0731742-oauvgvsc authors: Ivan Hariyanto, Timotius; Kurniawan, Andree title: Tocilizumab administration is associated with the reduction in biomarkers of coronavirus disease 2019 infection date: 2020-12-17 journal: J Med Virol DOI: 10.1002/jmv.26698 sha: ac7d20d0953ed0045b6714fbb9f784f3e1ffd788 doc_id: 731742 cord_uid: oauvgvsc Coronavirus disease 2019 (COVID‐19) has caused a significant impact on all aspects of life, with the number of death cases still increasing. Therefore, identification of potential treatment for reducing the severity of the disease is important. Currently, the data regarding the effectiveness of tocilizumab as treatment agents for COVID‐19 infection is still conflicting. This study aims to give clear evidence regarding the potential benefit of tocilizumab in reducing the biomarkers of COVID‐19 infection. We systematically searched the PubMed Central database using specific keywords related to our aims until July 24th, 2020. All articles published on COVID‐19 and tocilizumab were retrieved. A total of 9 studies with a total of 577 patients were included in our analysis. Our meta‐analysis showed that tocilizumab treatment is associated with reduction of C‐reactive protein (mean difference [MD]: −106.69 mg/L [95% confidence interval [CI]: −146.90, −66.49 mg/L], p < .00001; I (2) = 98%, random‐effect modeling), d‐dimer (MD: −3.06 mg/L [95% CI: −5.81, −0.31 mg/L], p = .03; I (2) = 98%, random‐effect modeling), Ferritin (MD: −532.80 ng/ml [95% CI: −810.93, −254.67 ng/ml], p = .0002; I (2) = 25%, random‐effect modeling), procalcitonin (MD: −0.67 ng/ml [95% CI: −1.13, −0.22 ng/ml], p = .004; I (2) = 92%, random‐effect modeling], and increment in the levels of lymphocyte count (MD: 0.36 × 10(3)/μl [95% CI: 0.18, 0.54 × 10(3)/μl], p < .0001; I (2) = 88%, random‐effect modeling). Administration of tocilizumab is effective in reducing the biomarkers of the COVID‐19 infection. Four months have passed since coronavirus disease 2019 (COVID- 19) was declared as a pandemic disease by the World Health Organization, but the number of positive and death cases from COVID-19 is still increasing. This disease has caused a significant burden on all aspects of life across the world. Several comorbidities have been demonstrated to be associated with the development of severe outcomes from infection, such as hypertension, diabetes, cardiovascular disease, dyslipidemia, thyroid disease, and pulmonary disease. [1] [2] [3] The pathogenesis of severe COVID-19 is related to the development of cytokine storm caused by robust activation of the immune system and hyperinflammation that will result in the increment of the inflammatory markers, such as C-reactive protein (CRP), procalcitonin (PCT), and also reduction of lymphocyte count. Meta-analysis has shown that several markers, such as CRP, D-dimer, ferritin, PCT, and lymphocyte count, can be used to indicate the severe outcome of COVID-19. 4 The presence of these COVID-19 patients, and one of the agents is tocilizumab, an interleukin-6 (IL-6) inhibitor. Tocilizumab has been approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and giant cell arteritis. 5 Recently, tocilizumab has been offered to help in reducing the proinflammatory cytokines in COVID-19 and preventing the cytokine storm syndrome that could contribute to the development of the severe outcome. However, the evidence regarding the potential benefit of tocilizumab in COVID-19 patients is still conflicting. A meta-analysis is therefore required to aid in solving this problem. This article aims to explore the potential benefit of tocilizumab in reducing the biomarkers of COVID-19 infection. A search of the literature was conducted on PubMed Central using the keywords "tocilizumab" AND "coronavirus disease 2019" OR "COVID-19," between 2019 and the present time (July 24th, 2020) with language restricted to English only. The title, abstract, and full text of all articles identified that matched the search criteria were assessed, and those reporting the comparison of pre-and posttocilizumab treatment with the data regarding laboratory parameters were included in this meta-analysis. The references of all identified studies were also analyzed (forward and backward citation tracking) to identify other potentially eligible articles. A meta-analysis was performed using Review Manager 5.4 (Cochrane Collaboration) software. Continuous variables were calculated using the Inverse-Variance formula with random-effects models. We used the I 2 statistic to assess the heterogeneity, value of less than 25%, 26%-50%, and greater thn 50% considered as low, moderate, and high degrees of heterogeneity, respectively. The effect estimate was reported as mean difference (MD) along with its 95% confidence intervals (CIs) for continuous variables, respectively. p Value was two-tailed, and the statistical significance was set at ≤.05. When data were reported as medians and interquartile ranges, we would convert them to means and standard deviations for metaanalytical pooling using the formula by Wan et al. 6 A total of 1,574 records were obtained through systematic electronic searches and other ways. After screening titles, abstracts, and full texts, nine studies 7-15 with a total of 577 COVID-19 patients were included in the meta-analysis. The essential characteristics of included studies are summarized in Table 1 , while Figure 1 increased. 18, 19 Moreover, IL-6 can also induce the release of hepcidin from the liver that blocks the iron-exporter (ferroportin), and eventually results in hyperferritinemia. Hyperferritinemia will give rise to ferroptosis, with high oxidative stress and lipoperoxidation that can precipitate the inflammatory or immune overresponse (cytokine storm). 20 All of these combinations will result in the development of severe outcomes of the disease. Tocilizumab specifically binds soluble and membrane-bound IL-6 receptors (sIL-6R and mIL-6R) and inhibits sIL-6R-and mIL-6R-mediated signal transduction. Therefore, by inhibiting IL-6 through tocilizumab administration, we can reduce the incidence of cytokine storm, preventing the overt inflammatory and coagulation cascade, also preventing the ferroptosis from happening. All of those associated markers (CRP, D-dimer, ferritin, PCT, lymphocyte count) will then follow to show improvement (by either reduction or increment). The authors declare that there are no conflict of interests. The data that support the findings of this study are openly available in PubMed at http://pubmed.ncbi.nlm.nih.gov/, reference number 4-12. Anemia is associated with severe coronavirus disease 2019 (COVID-19) infection Thyroid disease is associated with severe coronavirus disease 2019 (COVID-19) infection Dyslipidemia is associated with severe coronavirus disease 2019 (COVID-19) infection Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range Tocilizumab for the treatment of severe coronavirus disease 2019 Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up Feasibility of tocilizumab in ICU patients with COVID-19 Subcutaneous tocilizumab treatment in patients with severe COVID-19-related cytokine release syndrome: an observational cohort study Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study Tocilizumab treatment for cytokine release syndrome in hospitalized COVID-19 patients: survival and clinical outcomes Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia Effective treatment of severe COVID-19 patients with tocilizumab Why tocilizumab could be an effective treatment for severe COVID-19? Rational use of tocilizumab in the treatment of novel coronavirus pneumonia IL-6 pathway in the liver: from physiopathology to therapy Prognostic value of interleukin 6, procalcitonin, and C-reactive protein levels in intensive care unit patients during first increase of fever COVID-19: hemoglobin, iron, and hypoxia beyond inflammation. A narrative review